Sclareol prevents ovariectomy-induced bone loss in vivo and inhibits osteoclastogenesis in vitro via suppressing NF-κB and MAPK/ERK signaling pathways-Reference-Cited by-全球学者库

Sclareol prevents ovariectomy-induced bone loss in vivo and inhibits osteoclastogenesis in vitro via suppressing NF-κB and MAPK/ERK signaling pathways

Published:2019 Issue:10 Volume:10 Page:6556-6567
ISSN:2042-6496
Container-title:Food & Function
language:en
Short-container-title:Food Funct.

Author:

Jin Haiming¹²³⁴⁵,Shao Zhenxuan¹²³⁴⁶,Wang Qingqing¹²³⁴⁵,Miao Jiansen⁶⁷³⁴,Bai Xueqin⁸⁹³⁴,Liu Qian¹⁰¹¹¹²⁴,Qiu Heng⁵¹³¹⁴¹⁵,Wang Chao⁵¹³¹⁴¹⁵,Zhang Zengjie¹²³⁴⁶,Jennifer Tickner⁵¹³¹⁴¹⁵,Wang Xiangyang¹²³⁴,Xu Jiake¹²³⁴⁵^ORCID

Affiliation:

1. Key Laboratory of Orthopaedics of Zhejiang Province

2. The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical Universtiy

3. Wenzhou

4. China

5. School of Biomedical Sciences

6. The Second School of Medicine

7. Wenzhou Medical University

8. Department of Radiology

9. First Affiliated Hospital of Wenzhou Medical University

10. Research Centre for Regenerative Medicine and Guangxi Key Laboratory of Regenerative Medicine

11. Guangxi Medical University

12. Guangxi

13. The University of Western Australia

14. Perth

15. Western Australia

Abstract

Postmenopausal osteoporosis (PMO) is a progressive disease occurring in elderly postmenopausal women that is characterized by low bone mass and impaired bone quality.

Funder

Arthritis Foundation of Australia

University of Western Australia

National Health and Medical Research Council

National Natural Science Foundation of China

Natural Science Foundation of Guangxi Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Medicine,Food Science

Link

http://pubs.rsc.org/en/content/articlepdf/2019/FO/C9FO00206E